奥精医疗
(688613)
| 流通市值：22.78亿 | | | 总市值：22.78亿 |
| 流通股本：1.37亿 | | | 总股本：1.37亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 48,679,881.28 | 223,736,817.67 | 156,057,979.41 | 100,036,945.54 |
| 营业收入 | 48,679,881.28 | 223,736,817.67 | 156,057,979.41 | 100,036,945.54 |
| 二、营业总成本 | 50,705,307.96 | 233,158,629.73 | 162,013,922.68 | 107,505,776 |
| 营业成本 | 19,012,925.62 | 70,121,192.23 | 48,541,200.01 | 36,896,965.89 |
| 税金及附加 | 1,065,347.81 | 5,297,365.55 | 3,787,758.65 | 2,586,417.94 |
| 销售费用 | 8,653,896.18 | 55,742,494.46 | 37,648,031.3 | 22,703,352.26 |
| 管理费用 | 12,625,188.84 | 60,696,687.22 | 43,062,612.17 | 28,655,445.67 |
| 研发费用 | 9,001,881.31 | 39,249,862.32 | 27,453,429.72 | 15,730,815.05 |
| 财务费用 | 346,068.2 | 2,051,027.95 | 1,520,890.83 | 932,779.19 |
| 其中:利息费用 | - | 2,375,078.39 | 1,745,187.62 | 1,181,869.43 |
| 其中:利息收入 | - | 356,498.86 | -293,862.46 | -272,086.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,114,066.71 | 13,054,629.26 | 9,867,996.01 | 6,907,221.52 |
| 加:投资收益 | - | 124,271.64 | 39,774.48 | 15,855.8 |
| 资产处置收益 | -88,678.97 | 464,678.56 | 154,087.33 | 170,568.35 |
| 资产减值损失(新) | - | -161,868.18 | - | - |
| 信用减值损失(新) | - | 4,360,036.33 | 3,759,669.94 | 3,759,659.92 |
| 其他收益 | 139,834.66 | 3,578,431.73 | 2,853,312.23 | 2,123,912.73 |
| 四、营业利润 | 1,139,795.72 | 11,998,367.28 | 10,718,896.72 | 5,508,387.86 |
| 加:营业外收入 | - | 292,339.61 | 30,351.03 | 29,626.21 |
| 减:营业外支出 | 1,103.55 | 3,150.31 | 2,686.18 | 294.35 |
| 五、利润总额 | 1,138,692.17 | 12,287,556.58 | 10,746,561.57 | 5,537,719.72 |
| 减:所得税费用 | 620,086.38 | 2,785,201.58 | 150,793.13 | 1,365.75 |
| 六、净利润 | 518,605.8 | 9,502,355 | 10,595,768.44 | 5,536,353.97 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 518,605.8 | 9,502,355 | 10,595,768.44 | 5,536,353.97 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,410,974.64 | 13,839,244.09 | 13,940,614.52 | 7,975,343.63 |
| 少数股东损益 | -892,368.84 | -4,336,889.09 | -3,344,846.08 | -2,438,989.66 |
| 扣除非经常损益后的净利润 | -1,275,782.66 | -958,637.05 | 3,104,487.88 | -1,784.08 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0.1 | 0.1 | 0.06 |
| (二)稀释每股收益 | 0.01 | 0.1 | 0.1 | 0.06 |
| 八、其他综合收益 | -389,686.31 | 444,836.95 | 770,228.41 | 1,053,697.1 |
| 归属于母公司股东的其他综合收益 | -389,686.31 | 444,836.95 | 770,228.41 | 1,053,697.1 |
| 九、综合收益总额 | 128,919.49 | 9,947,191.95 | 11,365,996.85 | 6,590,051.07 |
| 归属于母公司股东的综合收益总额 | 1,021,288.33 | 14,284,081.04 | 14,710,842.93 | 9,029,040.73 |
| 归属于少数股东的综合收益总额 | -892,368.84 | -4,336,889.09 | -3,344,846.08 | -2,438,989.66 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-30 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |